Rising Promoter Stakes: What’s Behind the Surge in These Indian Stocks? 

By finchetak.com – Date: August 18, 2025

In the latest corporate shareholding disclosures, several Indian companies have witnessed a notable increase in promoter holdings. While this often signals management’s confidence in their business outlook, the accompanying financials reveal a more layered story. Below, we look at six companies that saw the steepest rise in promoter stake, ranked by percentage increase.

1. Orient Cement – Promoter holding ↑ 34.80%

• CMP: ₹233.82 | P/E: 18.48 | Market Cap: ₹4,804 Cr

• Quarterly Profit: ₹205.37 Cr (+459% YoY), Sales: ₹866.48 Cr (+24%)

• ROCE: 8.83% | Profit Growth: 48.91% | Debt: ₹69.73 Cr

• Opinion: Good

With the sharpest increase in promoter stake, Orient Cement shows robust quarterly profit growth and moderate leverage, though margins remain a point to watch.

2. AAVAS Financiers – Promoter holding ↑ 22.50%

• CMP: ₹1,658 | P/E: 22.35 | Market Cap: ₹13,124 Cr

• Quarterly Profit: ₹139.23 Cr (+10%), Sales: ₹627.56 Cr (+16%)

• ROCE: 10.10% | Profit Growth: 15.81% | Debt: ₹13,918 Cr

A leading NBFC, AAVAS shows steady earnings growth. However, high debt levels warrant careful monitoring even as promoters boost their stake.

3. ITD Cementation – Promoter holding ↑ 20.82%

• CMP: ₹768.40 | P/E: 32.21 | Market Cap: ₹13,200 Cr

• Quarterly Profit: ₹137.21 Cr (+37%), Sales: ₹2,542.37 Cr (+7%)

• ROCE: 27.64% | Profit Growth: 27.39% | Debt: ₹961 Cr

Strong operational performance and improving profitability back the increase in promoter stake, though valuations appear relatively high.

4. Cohance Life Sciences – Promoter holding ↑ 16.31%

• CMP: ₹913.85 | P/E: 101.15 | Market Cap: ₹34,961 Cr

• Quarterly Profit: ₹46.40 Cr (-31% YoY), Sales: ₹549.31 Cr (+13%)

• ROCE: 33.03% | Profit Growth: 35.52% | Debt: ₹279 Cr

• 
  

Despite healthy ROCE, falling quarterly profits and a steep P/E multiple make this stock riskier in the near term, even with promoter confidence.

5. Sanofi Consumer – Promoter holding ↑ 10.87%

• CMP: ₹5,158 | P/E: 60.04 | Market Cap: ₹11,879 Cr

• Quarterly Profit: ₹60.70 Cr (+23%), Sales: ₹220.90 Cr (+28%)

• ROCE: 111.44% | Profit Growth: -12.07% | Debt: ₹28 Cr

A strong return ratio and low debt levels are positives, though declining profit growth tempers the outlook.

Final Take

Promoter stake hikes indicate stronger involvement and conviction from company owners. However, the financial picture varies: while firms like Orient Cement and ITD Cementation show profit momentum, others such as Cohance Life Sciences face near-term risks despite increased ownership.

This review reflects our opinions on business stability and risk based on reported numbers, and is not a stock investment recommendation.